Approximately 920 000 children die of pneumonia annually before their fifth birthday.
1 There is a critical need to provide greater access to appropriate and effective treatment. Treatment of bacterial pneumonia requires an effective antibiotic used in adequate doses for an appropriate duration. A 3-day course of twice-daily amoxicillin is recommended by the World Health Organization (WHO) as first-line treatment of nonsevere fast-breathing pneumonia among immune-competent children aged 5 years or less.
2 The WHO’s integrated management of childhood illness (IMCI) guidelines identify fast-breathing pneumonia in children with cough or difficult breathing who demonstrate fast breathing without WHO danger signs.
3 However, not all cases of fast breathing are bacterial pneumonia. Indeed, the majority of fast-breathing pneumonia cases are likely not pneumonia at all. There are many reasons that a child might demonstrate fast breathing, and not all indicate disease.
4-7 Thus, isolated fast breathing may not be appropriately sensitive nor specific for diagnosing pneumonia,
8 making antibiotic treatment unnecessary. Although it is relatively well tolerated among children, amoxicillin has side effects and causes serious but rare adverse events.
9 Furthermore, inappropriate antibiotic use may lead to antibiotic resistance.
10-15